In vitro diagnostics market size is expected to grow from USD 108 billion in 2024 to USD 113 billion in 2025 and USD 190 billion by 2035, at a CAGR of 5.3%

The Report Covers the Global In-Vitro Diagnostics (IVD) Market is Segmented By Product (Reagents and Kits, Instruments), By Test Type (Clinical Chemistry, Molecular Diagnostics, Immunodiagnostics, Hematology, and Others), By Usability (Disposable IVD Devices, and Reusable IVD Devices), By Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), By End User (Hospitals Laboratories, Clinical Laboratories, Point-of-care Testing Centers, Academic Institutes, Patients, and Others), and Region Forecast 2019-2030. Key Players covered in this report are Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Becton, Dickinson, and Company (BD), Bio-Rad Laboratories, Agilent Technologies, QIAGEN, Hologic, Cepheid, LumiraDx, and Roche Molecular Systems.

In 2024, the global in-vitro diagnostics market had a revenue of almost 99 billion U.S. dollars. Between 2020 and 2021, the IVD market size increased significantly, going from around 76 billion U.S. dollars to just under 100 billion U.S. dollars.

In 2020, the in vitro-diagnostics market is expected to be dominated by consumable products with a share of 70 percent. The statistic shows the estimated distribution of the global in-vitro diagnostics market in 2020 and a forecast for 2030, by type of product.

The In Vitro Diagnostics (IVD) market is projected to grow at a CAGR of 5-6%, driven by factors such as the increasing prevalence of chronic and infectious diseases, rising demand for personalised medicine, technological advancements enhancing diagnostic accuracy and efficiency, growing investments in healthcare infrastructure, and the shift towards non-invasive and rapid testing methods improving […]

The Europe IVD market report segments the industry into By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, and more), By Product (Instrument, Reagents, and more), By Usability (Disposable IVD Devices, and more), By Application (Infectious Disease, Diabetes, and more), By End User (Diagnostic Laboratories, and more) and Geography.

In 2023, the In-Vitro Diagnostics (IVD) Market reached a value of USD 83.63 billion, and it is projected to surge to USD 114.02 billion by 2030.

The Mexico in-vitro diagnostics market grew a CAGR of 17.10% during the period 2025-2034. Analysis of human samples offers physicians with vital information to properly diagnose, treat, and prevent illnesses. Several leading companies offer in-vitro diagnostic (IVD) solutions that deliver rapid, sensitive results while minimizing cost and complexity. Modern in-vitro diagnostics (IVDs) enable better diagnosis for prevention and management of infectious and chronic diseases. In-vitro diagnostics can help identify early warning signs and individual risk factors, generating new openings for prevention and early intervention. Some in-vitro diagnostics range beyond the laboratory, hospital or doctor’s office, enabling patients with chronic illnesses to self-monitor and manage their own conditions. These factors are expected to drive market growth.

The China In-Vitro Diagnostics (IVD) market presents a significant growth opportunity, driven by factors such as a rising prevalence of chronic diseases, an aging population, increasing healthcare expenditure, and improving healthcare infrastructure. While precise figures for market size and CAGR are unavailable from the prompt, based on industry reports and trends, we can estimate the 2025 market size to be approximately $15 billion USD. Considering a robust growth trajectory projected for the Chinese healthcare sector, a conservative Compound Annual Growth Rate (CAGR) of 8-10% for the forecast period 2025-2033 seems plausible. This would place the market value at approximately $30-$40 billion USD by 2033. Key market segments include clinical chemistry, immunodiagnostics, molecular diagnostics, and hematology, with applications spanning hospitals, clinics, and diagnostic laboratories. The market's growth is further fueled by technological advancements, such as the adoption of automation and point-of-care testing, increasing demand for personalized medicine, and government initiatives promoting improved disease prevention and management. However, challenges remain. Pricing pressures, particularly in the context of government regulation and reimbursement policies, could impact profitability. Furthermore, competition from both domestic and international players necessitates continuous innovation and strategic partnerships for market leadership. The increasing focus on data security and regulatory compliance also presents significant hurdles. Despite these constraints, the long-term outlook for the China IVD market remains positive, fueled by the country's continued economic development and a growing emphasis on preventative healthcare. Companies like Abbott Laboratories, Siemens Healthineers, and Roche, along with several prominent Chinese players, are strategically positioning themselves to capitalize on this burgeoning market. The competitive landscape is dynamic, demanding adaptability and a robust understanding of the regulatory and economic climate within China.

The GCC In Vitro Diagnostics Market report segments the industry into By Technique (Histochemistry, Molecular Diagnostics, and more), By Product (Instrument, and more), By Usability (Disposable IVD Device, and more), By Application (Infectious Disease, and more), By End User (Diagnostic Laboratories, and more), and By Diagnostic Approach (Point-of-Care Diagnostics, and more).

The In Vitro Diagnostics Market estimated size and share is projected to exceed USD 152.62 billion by 2034, with a forecasted CAGR of 6.7% during the period.

Next-generation IVD market was valued at $86.21 billion in 2022 and is expected to reach $152.62 billion by 2033, growing at a CAGR of 5.41% between 2023 & 2033

In 2021, Germany had the largest in vitro diagnostics (IVD) market size in Europe at over 6.3 billion euros. This was followed by France with a market size of 2.6 billion euros, and Italy at 2.1 billion euros.

The Italy In Vitro Diagnostics Market size was valued at USD 4224.01 USD Million in 2023 and is projected to reach USD 6393.41 USD Million by 2032, exhibiting a CAGR of 6.1 % during the forecast period. In vitro diagnostics (IVD) refer to medical tests conducted using bodily samples like blood or tissue in a controlled environment outside the living organism (in vitro). These tests play a critical role in diagnosing diseases, monitoring therapy progress, and predicting health outcomes. They are categorized into clinical chemistry, immunochemistry, molecular diagnostics, and microbiology, each serving distinct diagnostic purposes. Key features include high accuracy, rapid results, and minimal invasiveness compared to traditional diagnostic methods.IVDs find applications across various medical disciplines, including oncology, infectious diseases, and genetic testing, enabling personalized treatment plans and early disease detection. Their benefits include improving patient outcomes through timely intervention, reducing healthcare costs, and supporting evidence-based medicine.

The Netherlands In Vitro Diagnostics Market report segments the industry into By Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Haematology, and more), By Product (Instrument, Reagent, and more), By Usability (Disposable IVD Devices, and more), By Application (Infectious Disease, Diabetes, and more), and By End User (Diagnostic Laboratories, Hospitals and Clinics, and more).

In 2021, Switzerland had the largest in vitro diagnostics (IVD) market size per capita in Europe with almost 89 euros spent per person in the IVD industry. This was followed by Germany who had an expenditure of 75.8 euros per person.

Europe In-Vitro Diagnostics Market is projected to reach USD 36.93 billion by 2032, growing at a CAGR of 4.5% from 2024-2032.

This statistic describes the top 10 medical technology companies for in vitro diagnostics in 2017 and 2024, based on market share. In 2017, Sysmex accounted for 4.4 percent of the global market for in vitro diagnostics. By 2024, this share is expected to increase slightly to 4.5 percent. In vitro diagnostics allows for medical professionals to detect diseases, conditions, and infections. These tests can be conducted within a laboratory and sometimes at within a patient's home.

Get detailed insights into the current valuation of In-Vitro Diagnostics market size, including growth analysis, current market status and future market projections.

The UK In-Vitro Diagnostics Market report segments the industry into By Technique (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Other Techniques), By Product (Instrument, Reagent, Other Products), By Usability (Disposable IVD Devices, Reusable IVD Devices), By Application (Infectious Disease, Diabetes, Cancer/Oncology, and more), and By End-Users (Diagnostic Laboratories, Hospitals and Clinics, and more).